Le ultime

Novità

Resta informato sugli ultimi sviluppi e gli ultimi risultati di TRICALS. Qui riferiamo i nostri progressi e ciò che viene realizzato grazie alla nostra collaborazione su larga scala. Naviga e leggi le ultime novità per restare aggiornato sul nostro viaggio di ricerca di un trattamento per la SLA.

Over 200 patients participate in Lighthouse II study worldwide
Over 200 patients participate in Lighthouse II study worldwide
The Lighthouse II study is a phase 3 clinical trial that compares…
Resta in [u]contatto[/u]

Resta in contatto

Ti piacerebbe tenerti aggiornato sulle ultime novità di TRICALS? Fai clic sul pulsante sotto per iscriverti alla nostra newsletter

ENCALS consensus statement on NurOwn
ENCALS consensus statement on NurOwn
Background Given the interest around the use of stem cells in ALS,…
Apellis reports discontinuation of MERIDIAN study
Apellis reports discontinuation of MERIDIAN study
Pharmaceutical company Apellis has announced the discontinuation of the open-label phase of…
Recording of virtual meeting – Adherence and retention in ALS clinical trials
Recording of virtual meeting – Adherence and retention in ALS clinical trials
On March 22, 2023, TRICALS organised its first virtual meeting: ‘Adherence and retention…
COURAGE-ALS trial discontinued due to disappointing results
COURAGE-ALS trial discontinued due to disappointing results
The company Cytokinetics has announced early termination of the COURAGE-ALS study. An…
TRICALS consensus statement on Tofersen
TRICALS consensus statement on Tofersen
OPINION: The consensus view of TRICALS neurologists is that Tofersen shows clear…
Lo Studio ATLAS: uno studio clinico per le persone che vogliono contribuire alla ricerca sulla SOD1 nella SLA
Lo Studio ATLAS: uno studio clinico per le persone che vogliono contribuire alla ricerca sulla SOD1 nella SLA
Lo studio clinico valuta l’efficacia e la sicurezza di un farmaco sperimentale…
Measuring treatment effects based on patient preference
Measuring treatment effects based on patient preference
To evaluate the effect of an investigational drug in ALS clinical trials,…
TRICALS Enrols First Participants in Phase 3 MAGNET platform trial for ALS
TRICALS Enrols First Participants in Phase 3 MAGNET platform trial for ALS
TRICALS (the Treatment Research Initiative to Cure ALS), in collaboration with ALS…
USA: new law promises $100 million for ALS research
USA: new law promises $100 million for ALS research
A new law has been passed in the United States to give…